Integrated Filing — IndAS

General information about company
Scrip Code	500420
NSE Symbol	TORNTPHARM
MSEI Symbol	NOTLISTED
ISIN	INE685A01028
Name of company	TORRENT PHARMACEUTICALS LIMITED
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-Apr-2024
Date of end of financial year	31-Mar-2025
Date of board meeting when results were approved	20-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	13-May-2025
Description of presentation currency	INR (in Actuals)
Reporting Type	Quarterly
Reporting Quarter	Fourth quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited for the quarter ended	Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Audited
Segment Reporting	Single segment
Description of single segment	Generic Formulation Business
Start date and time of board meeting	20-May-2025   14:20:00
End date and time of board meeting	20-May-2025   16:30:00
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?	Yes
Latest Date on which RPT policy is updated	2025-05-20
Indicate Company website link for updated RPT policy of the Company	https://www.torrentpharma.com/assets/RPT_policy_fa81df8739.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No
Not applicable during this quarter n

Financial Results Ind-AS
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-Jan-2025	01-Apr-2024
B	Date of end of reporting period	31-Mar-2025	31-Mar-2025
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1	Income
	Revenue from operations	24330000000	96820000000
	Other income	150000000	320000000
	Total income	24480000000	97140000000
2	Expenses
(a)	Cost of materials consumed	4020000000	15180000000
(b)	Purchases of stock-in-trade	2050000000	7320000000
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-280000000	-90000000
(d)	Employee benefit expense	4160000000	16360000000
(e)	Finance costs	470000000	2130000000
(f)	Depreciation, depletion and amortisation expense	1900000000	7600000000
(f)	Other Expenses
1	Other Expenses	5700000000	22300000000
	Total other expenses	5700000000	22300000000
	Total expenses	18020000000	70800000000
3	Total profit before exceptional items and tax	6460000000	26340000000
4	Exceptional items	-240000000	-240000000
5	Total profit before tax	6220000000	26100000000
6	Tax expense
7	Current tax	1600000000	5410000000
8	Deferred tax	-120000000	1810000000
9	Total tax expenses	1480000000	7220000000
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
11	Net Profit Loss for the period from continuing operations	4740000000	18880000000
12	Profit (loss) from discontinued operations before tax	0	0
13	Tax expense of discontinued operations	0	0
14	Net profit (loss) from discontinued operation after tax	0	0
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
16	Total profit (loss) for period	4740000000	18880000000
17	Other comprehensive income net of taxes	-50000000	-410000000
18	Total Comprehensive Income for the period	4690000000	18470000000
19	Total profit or loss, attributable to
	Profit or loss, attributable to owners of parent
	Total profit or loss, attributable to non-controlling interests
20	Total Comprehensive income for the period attributable to
	Comprehensive income for the period attributable to owners of parent
	Total comprehensive income for the period attributable to owners of parent non-controlling interests
21	Details of equity share capital
	Paid-up equity share capital	1692300000	1692300000
	Face value of equity share capital	5	5
27	Details of debt securities
22	Reserves excluding revaluation reserve		74230000000
23	Earnings per share
i	Earnings per equity share for continuing operations
	Basic earnings (loss) per share from continuing operations	14	55.79
	Diluted earnings (loss) per share from continuing operations	14	55.79
ii	Earnings per equity share for discontinued operations
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
ii	Earnings per equity share
	Basic earnings (loss) per share from continuing and discontinued operations	14	55.79
	Diluted earnings (loss) per share from continuing and discontinued operations	14	55.79
24	Debt equity ratio	0.0034	0.0034
25	Debt service coverage ratio	0.0511	0.0408
26	Interest service coverage ratio	0.1528	0.1443
27	Disclosure of notes on financial results		1. Exceptional item for the quarter and year ended March 31, 2025 relates to a demand raised by the National Pharmaceutical Pricing Authority (NPPA) in 2017 concerning alleged overcharging, which was under judicial consideration before the Hon’ble Gujarat High Court. During the year, the Company submitted detailed representations, which were favourably considered by the NPPA. As a result, the Company’s legal exposure was substantially reduced. Following the issuance of a revised demand by the NPPA, the Company opted to settle the litigation and bring the matter to a definitive close. n n2. The Income Tax Act, 1961, provides an option to the Company for paying tax at reduced rates (lower tax rate) as per the provisions/conditions defined in the Income Tax Act, 1961 (Section 115BAA). With reference to the same, the Company had previously assessed the option of availing the lower tax rate under Section 115BAA, in future years, and accordingly applied a mixed tax rate of 25.17% for deferred tax items expected to reverse after transitioning into new regime and 34.94% for those expected to reverse before the transition. Based on the current-year evaluation of available MAT credits and deductions under Chapter VIA as at March 31, 2025, the Company has now assessed that it will transition to the new tax regime from FY 2025-26. Consequently, deferred tax balances expected to reverse in or after FY 2025-26 have been remeasured at 25.17%, resulting in a net reversal of deferred tax liabilities of Rs. 151 crores for the year ended March 31, 2025.

Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio

Statement of Asset and Liabilities
Particulars		Year ended (dd-mm-yyyy)
Date of start of reporting period		01-Apr-2024
Date of end of reporting period		31-Mar-2025
Whether results are audited or unaudited		Audited
Nature of report standalone or consolidated		Standalone
	Assets
1	Non-current assets
	Property, plant and equipment	31320000000
	Capital work-in-progress	3650000000
	Investment property	0
	Goodwill	3240000000
	Other intangible assets	40990000000
	Intangible assets under development	360000000
	Biological assets other than bearer plants	0
	Investments accounted for using equity method	0
	Non-current financial assets
	Non-current investments	4110000000
	Trade receivables, non-current	0
	Loans, non-current	30000000
	Other non-current financial assets	170000000
	Total non-current financial assets	4310000000
	Deferred tax assets (net)	0
	Other non-current assets	1060000000
	Total non-current assets	84930000000
2	Current assets
	Inventories	15610000000
	Current financial asset
	Current investments	1120000000
	Trade receivables, current	21710000000
	Cash and cash equivalents	1050000000
	Bank balance other than cash and cash equivalents	50000000
	Loans, current	40000000
	Other current financial assets	1250000000
	Total current financial assets	25220000000
	Current tax assets (net)	0
	Other current assets	2660000000
	Total current assets	43490000000
3	Non-current assets classified as held for sale
4	Regulatory deferral account debit balances and related deferred tax Assets
	Total assets	128420000000
	Equity and liabilities
1	Equity
	Equity attributable to owners of parent
	Equity share capital	1690000000
	Other equity	74230000000
	Total equity attributable to owners of parent	75920000000
	Non controlling interest
	Total equity	75920000000
2	Liabilities
	Non-current liabilities
	Non-current financial liabilities
	Borrowings, non-current	10210000000
	Trade payables, non-current
	(A) Total outstanding dues of micro enterprises and small enterprises	0
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	0
	Total Trade payable	0
	Other non-current financial liabilities	830000000
	Total non-current financial liabilities	11040000000
	Provisions, non-current	3380000000
	Deferred tax liabilities (net)	8280000000
	Deferred government grants, Non-current	0
	Other non-current liabilities	0
	Total non-current liabilities	22700000000
	Current liabilities
	Current financial liabilities
	Borrowings, current	15260000000
	Trade payables, current
	(A) Total outstanding dues of micro enterprises and small enterprises	230000000
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	7440000000
	Total Trade payable	7670000000
	Other current financial liabilities	3050000000
	Total current financial liabilities	25980000000
	Other current liabilities	1020000000
	Provisions, current	2070000000
	Current tax liabilities (Net)	730000000
	Deferred government grants, Current	0
	Total current liabilities	29800000000
3	Liabilities directly associated with assets in disposal group classified as held for sale
4	Regulatory deferral account credit balances and related deferred tax liability
	Total liabilities	52500000000
	Total equity and liabilites	128420000000
	Disclosure of notes on assets and liabilities

Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-Jan-2025	01-Apr-2024
Date of end of reporting period		31-Mar-2025	31-Mar-2025
Whether accounts are audited or unaudited		Audited	Audited
Nature of report standalone or consolidated		Standalone	Standalone
1	Segment Revenue (Income)
	(net sale/income from each segment should be disclosed)
	Total Segment Revenue
	Less: Inter segment revenue
	Revenue from operations
2	Segment Result
	Profit (+) / Loss (-) before tax and interest from each segment
	Total Profit before tax
	i. Finance cost
	ii. Other Unallocable Expenditure net off Unallocable income
	Profit before tax
3	(Segment Asset - Segment Liabilities)
	Segment Asset
	Total Segment Asset
	Un-allocable Assets	null	null
	Net Segment Asset	null	null
4	Segment Liabilities
	Segment Liabilities
	Total Segment Liabilities
	Un-allocable Liabilities	null	null
	Net Segment Liabilities	null	null
	Disclosure of notes on segments

Other Comprehensive Income
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-Jan-2025	01-Apr-2024
B	Date of end of reporting period	31-Mar-2025	31-Mar-2025
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone
	Other comprehensive income [Abstract]
1	Amount of items that will not be reclassified to profit and loss
1	Amount of items that will not be reclassified to profit and loss	-140000000	-330000000
	Total Amount of items that will not be reclassified to profit and loss	-140000000	-330000000
2	Income tax relating to items that will not be reclassified to profit or loss	-10000000	-80000000
3	Amount of items that will be reclassified to profit and loss
1	Amount of items that will be reclassified to profit and loss	140000000	-230000000
	Total Amount of items that will be reclassified to profit and loss	140000000	-230000000
4	Income tax relating to items that will be reclassified to profit or loss	60000000	-70000000
5	Total Other comprehensive income	-50000000	-410000000

Cash flow statement, indirect
Particulars				Year ended (dd-mm-yyyy)
A	Date of start of reporting period			2024-04-01
B	Date of end of reporting period			2025-03-31
C	Whether results are audited or unaudited			Audited
D	Nature of report standalone or consolidated			Standalone
Part I	Blue color marked fields are non-mandatory.
	Statement of cash flows
	Cash flows from used in operating activities
	Profit before tax			26100000000
	Adjustments for reconcile profit (loss)
	Adjustments for finance costs			2130000000
	Adjustments for decrease (increase) in inventories			50000000
	Adjustments for decrease (increase) in trade receivables, current			-5810000000
	Adjustments for decrease (increase) in trade receivables, non-current			0
	Adjustments for decrease (increase) in other current assets			-620000000
	Adjustments for decrease (increase) in other non-current assets			0
	Adjustments for other financial assets, non-current			0
	Adjustments for other financial assets, current			0
	Adjustments for other bank balances			0
	Adjustments for increase (decrease) in trade payables, current			20000000
	Adjustments for increase (decrease) in trade payables, non-current			0
	Adjustments for increase (decrease) in other current liabilities			1210000000
	Adjustments for increase (decrease) in other non-current liabilities			0
	Adjustments for depreciation and amortisation expense			7600000000
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss			10000000
	Adjustments for provisions, current			0
	Adjustments for provisions, non-current			0
	Adjustments for other financial liabilities, current			0
	Adjustments for other financial liabilities, non-current			0
	Adjustments for unrealised foreign exchange losses gains			130000000
	Adjustments for dividend income			0
	Adjustments for interest income			10000000
	Adjustments for share-based payments			0
	Adjustments for fair value losses (gains)			0
	Adjustments for undistributed profits of associates			0
	Other adjustments for which cash effects are investing or financing cash flow			-190000000
	Other adjustments to reconcile profit (loss)			20000000
	Other adjustments for non-cash items			0
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships			0
	Total adjustments for reconcile profit (loss)			4540000000
	Net cash flows from (used in) operations			30640000000
	Dividends received			0
	Interest paid			0
	Interest received			0
	Income taxes paid (refund)			4900000000
	Other inflows (outflows) of cash			0
	Net cash flows from (used in) operating activities			25740000000
	Cash flows from used in investing activities
	Cash flows from losing control of subsidiaries or other businesses			0
	Cash flows used in obtaining control of subsidiaries or other businesses			780000000
	Other cash receipts from sales of equity or debt instruments of other entities			450000000
	Other cash payments to acquire equity or debt instruments of other entities			0
	Other cash receipts from sales of interests in joint ventures			0
	Other cash payments to acquire interests in joint ventures			0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships			0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships			100000000
	Proceeds from sales of property, plant and equipment			180000000
	Purchase of property, plant and equipment			4460000000
	Proceeds from sales of investment property			0
	Purchase of investment property			0
	Proceeds from sales of intangible assets			0
	Purchase of intangible assets			0
	Proceeds from sales of intangible assets under development			0
	Purchase of intangible assets under development			0
	Proceeds from sales of goodwill			0
	Purchase of goodwill			0
	Proceeds from biological assets other than bearer plants			0
	Purchase of biological assets other than bearer plants			0
	Proceeds from government grants			0
	Proceeds from sales of other long-term assets			0
	Purchase of other long-term assets			0
	Cash advances and loans made to other parties			0
	Cash receipts from repayment of advances and loans made to other parties			0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts			0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts			0
	Dividends received			0
	Interest received			10000000
	Income taxes paid (refund)			0
	Other inflows (outflows) of cash			0
	Net cash flows from (used in) investing activities	-4700000000
	Cash flows from used in financing activities
	Proceeds from changes in ownership interests in subsidiaries			0
	Payments from changes in ownership interests in subsidiaries			0
	Proceeds from issuing shares			0
	Proceeds from issuing other equity instruments			0
	Payments to acquire or redeem entity's shares			0
	Payments of other equity instruments			0
	Proceeds from exercise of stock options			0
	Proceeds from issuing debentures notes bonds etc			0
	Proceeds from borrowings			0
	Repayments of borrowings			7880000000
	Payments of lease liabilities			90000000
	Dividends paid			10830000000
	Interest paid			2240000000
	Income taxes paid (refund)			0
	Other inflows (outflows) of cash			0
	Net cash flows from (used in) financing activities			-21040000000
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes			0
	Effect of exchange rate changes on cash and cash equivalents
	Effect of exchange rate changes on cash and cash equivalents			0
	Net increase (decrease) in cash and cash equivalents			0
	Cash and cash equivalents cash flow statement at beginning of period			1050000000
	Cash and cash equivalents cash flow statement at end of period			1050000000